Adding Trabecular Bone Score (TBS) to FRAX and BMD enhances Fx risk prediction in osteoporosis. TBS is validated index of bone microarchitecture from LS spine DEXA. TBS is good at fragility Fx risk and monitoring response to OP Rx https://t.co/T7EStHyDBq https://t.co/sct79nTzBO

CMS billing data shows female MDs are 25% more likely than male MDs to leave academia (OR 1.25; 1.23-1.28); at all stages of their careers. At 5 yrs, attrition rate from academia was 34.2% (38.3% for females and 32.4% for male physicians). https://t.co/5wZKuYrdoB https://t.co/wNPGOCDSJ4

SGLT2 Inhibitors Reduce Gout Flares and CV Events A cohort analysis shows that gout patients initiating sodium–glucose cotransporter-2 inhibitors (SGLT2is) had lower serum urate levels and fewer gouty flares requiring ED visits or hospitalizations. https://t.co/fmz1j6pHgL https://t.co/XbqWxZRd97

US study shows 1635 adults receiving chiropractic spinal manipulation for radicular LBP receive significantly less gabapentin prescription (OR 0.53; 0.40 to 0.71; p<0.0001) over 1-year follow-up compared with those receiving usual medical care https://t.co/t0uTMdLEzO https://t.co/rCR04sMdRV

JAMA: cutaneous hallmarks of dermatomyositis. Printable Patient education overview. https://t.co/VKsxT34lga https://t.co/VGaFmsYUrP

Bringing pivotal clinical trials to you: announcing RheumNow’s Poster Hall, featuring previously presented, sponsor-generated clinical trial posters designed to educate and inform. https://t.co/GvX0lcCng6 https://t.co/IUfkj4emim

MMWR: Arthritis Among Children and Adolescents The CDC estimates that nearly 220,000 children and adolescents had arthritis during 2017–2021. https://t.co/pQnB3zV7sw https://t.co/nrLZ8Uazgh

Double blind RCT of 101 active AS patients with BASDAI ≥4 showed the IL-23 inhibitor, tildrakizumab was not superior to placebo after 24 weeks (ASAS20: 74% on tildrakizumab 200 mg vs 80% on PBO). Study was terminated after wk 24 interim analysis https://t.co/zZxiAk6A5o https://t.co/P1tNX8BN6C

EMA's CHMP adopted a positive opinion for 1st tocilizumab biosimilar, Tyenne® (from Fresenius Kab), for Rx of RA, systemic JIA, poly JIA, GCA, COVID-19 and CAR-T cell-induced cytokine release syndrome. No decision yet on IL6 biosimilar in USA https://t.co/w00yGfm3Vv https://t.co/UzxPvBf1nG

RNase Treatment of Autoimmune Disorders U1RNP complex, Ro/SSA and La/SSB are major RNA-containing autoantigens associated with autoimmune disorders. https://t.co/JhOk4rEdoG https://t.co/E8UxJ94ShN

Tofactitinib in PsA & RA: Nine Year Safety Data A real-world, post-marketing surveillance (PMS) of tofacitinib in PsA and RA shows a consistent pattern of safety with no new safety concerns identified. https://t.co/nVglUz6FJC https://t.co/t3dI5SzjJa